Elite Journal of Medicine. Volume 2 issue 6(2024), Pp. 1-9
https://epjournals.com/journals/EJM

Unveiling Platelet Dynamics in ART-Treated HIV Patients: A Comprehensive Review

Joseph Obiezu Chukwujekwu Ezeonwumelu[1] and *Emmanuel Ifeanyi Obeagu[2]

[1]Department of Clinical Pharmacy and Pharmacy Practice, Kampala International University, Uganda

[2]Department of Medical Laboratory Science, Kampala International University, Uganda

Abstract

Antiretroviral therapy (ART) has dramatically improved the life expectancy of HIV-infected individuals, transforming the disease into a manageable chronic condition. Despite these advancements, ART-treated HIV patients continue to experience significant alterations in platelet dynamics, which are crucial for both hemostasis and immune function. This review examines the complex interplay between HIV, ART, and platelet dynamics, focusing on the mechanisms driving these changes and their clinical implications. Platelet abnormalities, including thrombocytopenia and platelet hyperactivation, are common in HIV patients both before and after ART initiation. Chronic immune activation and systemic inflammation, hallmarks of HIV infection, persist even under effective ART and contribute to these alterations. Additionally, ART drugs themselves can influence platelet function in varying degrees, with protease inhibitors particularly implicated in promoting platelet activation and aggregation. Clinically, these platelet dynamics have significant implications for the management of HIV patients. Thrombocytopenia requires careful monitoring and intervention to prevent severe complications, while platelet hyperreactivity contributes to an increased risk of cardiovascular events. Regular assessment of platelet counts and function is essential for early detection and management of these issues. Future research should focus on the long-term effects of ART on platelet dynamics and develop strategies to mitigate associated risks, ultimately improving the quality of life for HIV patients.

Keywords: *Platelet Dynamics, Antiretroviral Therapy, HIV, Immune Activation, Coagulation, Thrombocytopenia, Inflammation, Platelet Activation*

Introduction

The introduction of antiretroviral therapy (ART) has revolutionized the management of HIV infection, transforming it from a fatal disease into a chronic, manageable condition. ART effectively suppresses viral replication, reduces HIV-associated morbidity and mortality, and improves overall quality of life for those infected. However, despite these advancements, ART-

treated HIV patients continue to face numerous health challenges, including alterations in platelet dynamics. Platelets are not only essential for hemostasis but also play a significant role in immune responses and inflammation, areas that are critically impacted in HIV-infected individuals.[1-5] Thrombocytopenia, or low platelet count, is a common hematological complication observed in HIV-infected patients, occurring both in untreated and treated states. The pathogenesis of HIV-associated thrombocytopenia is multifactorial, involving direct effects of the virus on bone marrow megakaryocytes, increased platelet destruction, and impaired platelet production. ART typically leads to an improvement in platelet counts, yet this recovery is often incomplete and varies depending on the ART regimen, duration of therapy, and the patient's baseline platelet count. Understanding the dynamics of platelet count recovery and the factors influencing it is crucial for optimizing patient outcomes.[6-11]

Beyond thrombocytopenia, ART-treated HIV patients frequently experience platelet hyperactivation, contributing to a prothrombotic state and increased risk of cardiovascular events. Chronic immune activation and systemic inflammation, which persist despite effective ART, play a central role in this process. Elevated levels of pro-inflammatory cytokines, such as IL-6 and TNF-α, contribute to increased platelet activation and turnover, leading to platelet exhaustion and potential thrombocytopenia. These immune and inflammatory processes underscore the need for continuous monitoring and management of platelet function in HIV patients. The impact of ART on platelet dynamics extends beyond immune activation and inflammation. Different classes of ART drugs have varying effects on platelet function, with some, like protease inhibitors, being more prone to causing platelet activation and aggregation. Conversely, other ART classes such as integrase inhibitors and non-nucleoside reverse transcriptase inhibitors may have less pronounced effects on platelet activity. Understanding these drug-specific impacts is essential for tailoring ART regimens to minimize adverse hematological outcomes while effectively controlling HIV replication.[12-15] In this review, we aim to comprehensively explore the multifaceted interactions between HIV, ART, and platelet dynamics.

Platelet Dynamics in HIV Infection

Baseline Platelet Abnormalities

HIV infection is frequently associated with significant hematological complications, one of the most common being thrombocytopenia, characterized by a low platelet count.[16] This condition is observed in a substantial proportion of HIV-infected individuals, even before the initiation of antiretroviral therapy (ART). The mechanisms behind HIV-associated thrombocytopenia are multifaceted. Direct infection of megakaryocytes, the bone marrow cells responsible for platelet production, by HIV can lead to impaired platelet production. Additionally, HIV-induced immune dysregulation can result in increased platelet destruction through autoantibody formation or heightened phagocytic activity. The resulting thrombocytopenia poses a risk for bleeding complications and necessitates careful clinical management.

Impact of ART on Platelet Count

The initiation of ART generally leads to a rapid and significant improvement in platelet counts, a phenomenon attributable to the effective suppression of HIV replication and the consequent reduction in immune activation.[17] This improvement is often observed within the first few months of therapy. However, the degree of platelet count recovery can vary widely among individuals. Factors influencing this variability include the type of ART regimen employed, the duration of therapy, and the patient's baseline platelet count. For instance, patients with severe pre-treatment thrombocytopenia may experience a slower or less complete recovery. Despite these variations, the overall trend toward normalization of platelet counts with ART underscores the critical role of viral suppression in managing HIV-associated hematological abnormalities.

Chronic Immune Activation and Inflammation

Even with effective ART, chronic immune activation and systemic inflammation persist in many HIV-infected individuals.[18] These processes significantly impact platelet dynamics. Persistent immune activation is characterized by elevated levels of pro-inflammatory cytokines, such as IL-6 and TNF-α, which stimulate platelet production and activation. The continuous turnover and activation of platelets can lead to a state of platelet exhaustion, contributing to ongoing thrombocytopenia or dysfunctional platelets that are less effective in hemostasis. This inflammatory milieu not only affects platelet count and function but also predisposes patients to other complications, including cardiovascular diseases and coagulopathies.

Coagulation and Thrombotic Risk

HIV infection and ART are both associated with an increased risk of thrombotic events, reflecting a complex interplay between viral factors, host immune responses, and drug effects.[19] Platelet hyperreactivity, driven by chronic inflammation and immune dysregulation, plays a central role in this enhanced thrombotic risk. Elevated platelet activation markers and increased platelet-leukocyte aggregates are frequently observed in ART-treated HIV patients. Additionally, certain ART drugs, particularly protease inhibitors, can exacerbate these prothrombotic tendencies by altering lipid metabolism and endothelial function. These changes collectively contribute to an elevated risk of cardiovascular events, necessitating vigilant monitoring and management strategies to mitigate thrombotic risks in this population.

Direct Effects of ART on Platelets

The impact of ART on platelet dynamics is not uniform across different drug classes.[20] Protease inhibitors, for example, have been linked to increased platelet activation and aggregation, likely through mechanisms involving metabolic and inflammatory pathways. Conversely, integrase inhibitors and non-nucleoside reverse transcriptase inhibitors tend to have a less pronounced effect on platelet function. Understanding these drug-specific impacts is critical for optimizing ART regimens to balance effective HIV suppression with minimal adverse effects on platelet dynamics.

This knowledge can guide clinicians in selecting ART combinations that minimize the risk of thrombocytopenia and thrombotic complications, ultimately improving patient outcomes.

Mechanisms of Platelet Alterations in ART-Treated HIV Patients

Immune Activation and Inflammation

One of the central mechanisms driving platelet alterations in ART-treated HIV patients is chronic immune activation and persistent systemic inflammation.[21] Even with effective viral suppression through ART, many patients continue to experience elevated levels of immune activation markers. Pro-inflammatory cytokines such as IL-6, TNF-α, and interferon-gamma (IFN-γ) remain elevated and contribute significantly to platelet activation and turnover. These cytokines can stimulate megakaryocytes to produce more platelets, while also promoting the activation and aggregation of existing platelets. The resultant state is one of heightened platelet activation and increased risk of platelet consumption, potentially leading to platelet exhaustion and a tendency towards thrombocytopenia.[22-24]

Coagulation Pathways and Thrombotic Risk

ART-treated HIV patients are at an increased risk for thrombotic events, partly due to disruptions in coagulation pathways.[25] Chronic inflammation can lead to endothelial cell activation and dysfunction, a key factor in the development of a prothrombotic state. Endothelial cells, when activated, express higher levels of adhesion molecules and release pro-coagulant factors like von Willebrand factor (vWF). Additionally, activated platelets interact more readily with leukocytes, forming platelet-leukocyte aggregates that further propagate thrombus formation. This prothrombotic environment is exacerbated by certain ART drugs, especially protease inhibitors, which have been shown to affect lipid metabolism and increase the risk of atherosclerosis and other cardiovascular diseases.[26-27]

Direct Effects of ART on Platelets

Different ART regimens have direct effects on platelet function and dynamics, which vary depending on the drug class. Protease inhibitors, such as lopinavir and ritonavir, are particularly associated with increased platelet activation and aggregation. These drugs can alter lipid profiles, leading to dyslipidemia, which in turn can enhance platelet reactivity. Moreover, protease inhibitors have been implicated in inducing insulin resistance and increasing levels of pro-inflammatory cytokines, both of which contribute to a hypercoagulable state. On the other hand, integrase strand transfer inhibitors (INSTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) typically have a more neutral or even beneficial effect on platelet function, posing a lower risk of adverse hematological outcomes.[28-31]

Bone Marrow Suppression and Megakaryocyte Dysfunction

HIV itself can infect bone marrow cells, including megakaryocytes, leading to impaired platelet production. ART, while reducing viral load, does not entirely eliminate HIV from the bone marrow, and the residual viral presence can continue to affect megakaryocyte function.[32] Additionally, ART drugs, particularly nucleoside reverse transcriptase inhibitors (NRTIs), can cause mitochondrial toxicity, which may impair the proliferation and function of hematopoietic cells, including megakaryocytes. This mitochondrial dysfunction can result in reduced platelet production and contribute to thrombocytopenia, despite the overall improvement in platelet counts observed with ART initiation.

Immune-Mediated Platelet Destruction

Autoimmune mechanisms also play a role in platelet alterations in HIV-infected individuals. HIV infection can lead to the production of autoantibodies against platelet glycoproteins, resulting in immune-mediated platelet destruction.[33] ART can reduce the overall immune activation and autoantibody production, but these processes may not be completely reversed, leading to persistent platelet destruction in some patients. The presence of these autoantibodies necessitates ongoing monitoring and potentially the use of immunosuppressive therapies in severe cases of thrombocytopenia.

Clinical Implications

Management of Thrombocytopenia

Thrombocytopenia remains a common issue among HIV-infected individuals, even those receiving ART.[34] Effective management of thrombocytopenia involves identifying and addressing underlying causes, such as opportunistic infections, drug side effects, or autoimmune mechanisms. For instance, discontinuing medications known to exacerbate thrombocytopenia, like certain ART drugs or cotrimoxazole, may be necessary. In severe cases, treatments such as corticosteroids, intravenous immunoglobulin (IVIG), or splenectomy may be considered. Close monitoring of platelet counts is essential to prevent bleeding complications and guide appropriate therapeutic interventions.

Cardiovascular Risk Management

The heightened thrombotic risk in ART-treated HIV patients necessitates vigilant cardiovascular risk management.[35] Regular cardiovascular risk assessments, including monitoring lipid profiles and inflammatory markers, should be integrated into routine care. Lifestyle modifications, such as promoting a healthy diet, regular physical activity, and smoking cessation, are crucial in mitigating cardiovascular risks. Additionally, the use of statins or antiplatelet agents, such as aspirin, may be indicated in certain patients to manage dyslipidemia and reduce thrombotic risk. Clinicians should balance the benefits of ART in viral suppression with the potential cardiovascular side effects, tailoring treatment regimens to minimize adverse outcomes.

Monitoring and Risk Assessment

Routine monitoring of platelet counts and function is vital in ART-treated HIV patients to detect and manage hematological complications early.[36] Incorporating platelet-related biomarkers, such as mean platelet volume (MPV) and platelet distribution width (PDW), can enhance risk assessment for both bleeding and thrombotic events. Advanced diagnostic tools, including flow cytometry for platelet activation markers and imaging techniques for thrombus detection, may provide further insights into platelet dynamics and guide clinical decision-making. Developing comprehensive monitoring protocols that include these advanced assessments can improve the early detection and management of platelet-related complications.[37-38]

Personalized ART Regimens

Given the varying effects of different ART drugs on platelet dynamics, personalized ART regimens are essential for optimizing patient outcomes. Selecting ART combinations that minimize adverse effects on platelet function while effectively controlling HIV replication is critical. For example, avoiding protease inhibitors in patients with pre-existing cardiovascular risks or platelet abnormalities may be beneficial. Integrase strand transfer inhibitors (INSTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) may be preferred in such cases due to their more favorable impact on platelet function. Personalizing ART regimens based on individual patient profiles can help reduce the incidence of thrombocytopenia and thrombotic events.[39-40]

Future Research Directions

Further research is needed to elucidate the long-term effects of ART on platelet dynamics and the underlying mechanisms driving these changes. Studies investigating the impact of new ART drugs and combination therapies on platelet function will be essential in optimizing treatment protocols. Additionally, research into the role of inflammation and immune activation in platelet alterations can uncover novel therapeutic targets to mitigate these effects. Understanding the genetic and molecular factors influencing platelet responses to HIV and ART can also inform personalized medicine approaches, leading to more effective and tailored treatment strategies for HIV patients.[41]

Conclusion

The dynamics of platelets in HIV-infected individuals undergoing antiretroviral therapy (ART) present a complex and multifaceted clinical challenge. While ART has significantly improved the prognosis and quality of life for HIV patients, it does not entirely mitigate the issues related to platelet abnormalities, including thrombocytopenia and platelet hyperactivation. These platelet alterations are driven by persistent immune activation, systemic inflammation, and the direct effects of ART drugs. Chronic immune activation and inflammation continue to influence platelet function and coagulation pathways, increasing the risk of both bleeding complications and thrombotic events. Effective management of these hematological complications requires a comprehensive approach. This includes regular monitoring of platelet counts and function, early identification and treatment of thrombocytopenia, and proactive management of cardiovascular

risks. Personalized ART regimens, tailored to minimize adverse effects on platelet dynamics while maintaining effective viral suppression, are crucial for optimizing patient outcomes. Clinicians must balance the benefits of ART with its potential side effects, adjusting treatment plans based on individual patient profiles and risk factors.

References

1. Russell S, Seeley J. The transition to living with HIV as a chronic condition in rural Uganda: Working to create order and control when on antiretroviral therapy. Social science & medicine. 2010;70(3):375-382.
2. Vella S, Schwartländer B, Sow SP, Eholie SP, Murphy RL. The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. Aids. 2012;26(10):1231-1241.
3. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. AIDS: A Review. Newport International Journal of Public Health and Pharmacy (Nijpp). 2023;3(2):64-67.
4. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV infection and cardiovascular diseases: the obnoxious duos. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):95-99.
5. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. Elite Journal of Medicine, 2024; 2(1):10-22
6. Marchionatti A, Parisi MM. Anemia and thrombocytopenia in people living with HIV/AIDS: a narrative literature review. International Health. 2021 Mar;13(2):98-109.
7. Vishnu P, Aboulafia DM. Haematological manifestations of human immune deficiency virus infection. British journal of haematology. 2015 Dec;171(5):695-709.
8. Ifeanyi OE, Favour AA, Prayer NN. Updates on Human Immunodeficiency Virus and Platelets. Int. J. Adv. Res. Biol. Sci. 2020;7(6):1-7.
9. Miguez-Burbano MJ, Jackson Jr J, Hadrigan S. Thrombocytopenia in HIV disease: clinical relevance, physiopathology and management. Current Medicinal Chemistry-Cardiovascular & Hematological Agents. 2005;3(4):365-376.
10. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. Asian J Dental Health Sci. 2024; 30];3(2):7-14. http://ajdhs.com/index.php/journal/article/view/39
11. Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):9-19.
12. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV, 2024; 2(1): 16-30
13. Obeagu EI, Obeagu, GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. Elite Journal of Scientific Research and Review, 2024; 2(1): 37-50
14. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):11-24.

15. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. Journal home page: http://www. journalijiar. com.;12(01).
16. Marchionatti A, Parisi MM. Anemia and thrombocytopenia in people living with HIV/AIDS: a narrative literature review. International Health. 2021;13(2):98-109.
17. Younas M, Psomas C, Reynes J, Corbeau P. Immune activation in the course of HIV-1 infection: causes, phenotypes and persistence under therapy. HIV medicine. 2016;17(2):89-105.
18. Zicari S, Sessa L, Cotugno N, Ruggiero A, Morrocchi E, Concato C, Rocca S, Zangari P, Manno EC, Palma P. Immune activation, inflammation, and non-AIDS co-morbidities in HIV-infected patients under long-term ART. Viruses. 2019;11(3):200.
19. Madzime M, Rossouw TM, Theron AJ, Anderson R, Steel HC. Interactions of HIV and antiretroviral therapy with neutrophils and platelets. Frontiers in immunology. 2021; 12:634386.
20. Bluestein D, Chandran KB, Manning KB. Towards non-thrombogenic performance of blood recirculating devices. Annals of biomedical engineering. 2010; 38:1236-56.
21. Akinosoglou K, Kolosaka M, Schinas G, Delastic AL, Antonopoulou S, Perperis A, Marangos M, Mouzaki A, Gogos C. Association of Antiretroviral Therapy with Platelet Function and Systemic Inflammatory Response in People Living with HIV: A Cross-Sectional Study. Microorganisms. 2023;11(4):958.
22. Obeagu EI, Obeagu GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. Elite Journal of Scientific Research and Review. 2024;2(1):17-41.
23. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda. Elite Journal of Medicine. 2024;2(1):1-6.
24. Obeagu EI, GU EE. Understanding the Intersection of Highly Active Antiretroviral Therapy and Platelets in HIV Patients: A Review. Elite Journal of Haematology, 2024; 2 (3).:111-7.
25. Baker JV, Brummel-Ziedins K, Neuhaus J, Duprez D, Cummins N, Dalmau D, DeHovitz J, Lehmann C, Sullivan A, Woolley I, Kuller L. HIV replication alters the composition of extrinsic pathway coagulation factors and increases thrombin generation. Journal of the American Heart Association. 2013;2(4): e000264.
26. Obeagu EI, Obeagu GU. ART and Platelet Dynamics: Assessing Implications for HIV Patient Care. Elite Journal of Haematology. 2024;2(4):68-85.
27. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. Elite Journal of HIV. 2024;2(3):14-26.
28. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. Elite Journal of Haematology. 2024;2(3):10-24.
29. Obeagu EI, EE G. Understanding the Intersection of Highly Active Antiretroviral Therapy and Platelets in HIV Patients: A Review. Elite Journal of Haematology. 2024;2(3):111-7.
30. Obeagu EI, Obeagu GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. Elite Journal of Scientific Research and Review. 2024;2(1):1-6.
31. Obeagu EI, Obeagu GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. Elite Journal of Scientific Research and Review. 2024;2(1):1-6.

32. Tripathi AK, Misra R, Kalra P, Gupta N, Ahmad R. Bone marrow abnormalities in HIV disease. JAPI. 2005; 53:705-10.
33. Shenkman B, Rosenberg N, Einav Y. Platelet autoantibodies. InAutoantibodies 2014: 519-525. Elsevier.
34. Talargia F, Getacher L. Thrombocytopenia and associated factors among HIV infected patients in Pre-and post-anti-retroviral therapy, North East Ethiopia. Journal of Blood Medicine. 2021:741-748.
35. Henning RJ, Greene JN. The epidemiology, mechanisms, diagnosis and treatment of cardiovascular disease in adult patients with HIV. American journal of cardiovascular disease. 2023;13(2):101.
36. Goedel A, Müller S, Schwerdtfeger C, Zink A, Noe S, Bongiovanni D, Haller B, Spinner CD, Bernlochner I. Influence of antiretroviral therapy and cardiovascular disease on the immature platelet fraction in patients living with HIV. Platelets. 2020;31(6):756-762.
37. Obeagu EI, Obeagu GU. ART and Platelet Dynamics: Assessing Implications for HIV Patient Care. Elite Journal of Haematology. 2024;2(4):68-85.
38. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. Elite Journal of Haematology. 2024;2(3):10-24.
39. Obeagu EI, Obeagu GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. Elite Journal of Scientific Research and Review. 2024;2(1):1-6.
40. Shen Y, Liu T, Chen J, Li X, Liu L, Shen J, Wang J, Zhang R, Sun M, Wang Z, Song W. Harnessing artificial intelligence to optimize long-term maintenance dosing for antiretroviral-naive adults with HIV-1 infection. Advanced Therapeutics. 2020 Apr;3(4):1900114.
41. Obeagu EI, Obeagu GU. Platelet index ratios in HIV: Emerging biomarkers for immune health and disease management. Medicine. 2024 Mar 22;103(12):e37576.